These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2938301)

  • 1. Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuit.
    Matsuo T; Nakao K; Yamada T; Matsuo O
    Thromb Res; 1986 Jan; 41(1):33-41. PubMed ID: 2938301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation and platelet activation in hemodialysis: clinical results with PMMA.
    Coli L; Cianciolo G; Feliciangeli G; De Sanctis LB; Zanchelli F; Dalmastri V; De Pascalis A; Sestigiani E; Donati G; Stefoni S
    Contrib Nephrol; 1999; 125():111-9. PubMed ID: 9895435
    [No Abstract]   [Full Text] [Related]  

  • 3. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
    Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secreted platelet proteins with antiheparin and mitogenic activities in chronic renal failure.
    Guzzo J; Niewiarowski S; Musial J; Bastl C; Grossman RA; Rao AK; Berman I; Paul D
    J Lab Clin Med; 1980 Jul; 96(1):102-13. PubMed ID: 6446588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations in the circulating heparin levels during maintenance hemodialysis in patients with end-stage renal disease.
    Kaneva K; Bansal V; Hoppensteadt D; Cunanan J; Fareed J
    Clin Appl Thromb Hemost; 2013; 19(4):449-52. PubMed ID: 23463188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma beta-thromboglobulin and platelet factor 4 in patients with chronic renal failure and effect of hemodialysis.
    Endo Y; Mamiya S; Satoh M; Takahashi K; Harada T
    Tohoku J Exp Med; 1981 Dec; 135(4):349-58. PubMed ID: 6175048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Thromboglobulin may not reflect platelet activation during haemodialysis with the HeprAN membrane.
    Sagedal S; Sandvik L; Klingenberg O; Sandset PM
    Scand J Clin Lab Invest; 2017 Dec; 77(8):679-684. PubMed ID: 29117741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison between the use of recombinant hirudin and heparin during hemodialysis.
    van Wyk V; Badenhorst PN; Luus HG; Kotzé HF
    Kidney Int; 1995 Oct; 48(4):1338-43. PubMed ID: 8569097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble P-selectin is released from activated platelets in vivo during hemodialysis.
    Kawabata K; Nagake Y; Shikata K; Fukuda S; Nakazono H; Takahashi M; Ichikawa H; Makino H
    Nephron; 1998; 78(2):148-55. PubMed ID: 9496730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous comparison of thrombogenic reactions to different combinations of anticoagulants, activated clotting times, and materials.
    Nagai M; Iwasaki K; Umezu M; Ozaki M
    J Biomed Mater Res B Appl Biomater; 2014 Nov; 102(8):1605-12. PubMed ID: 24652689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis.
    van Wyk V; Badenhorst PN; Kotzé HF
    Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study.
    Borm JJ; Krediet R; Sturk A; ten Cate JW
    Haemostasis; 1986; 16 Suppl 2():59-68. PubMed ID: 2943643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency.
    Ota K; Akizawa T; Hirasawa Y; Agishi T; Matsui N
    Nephrol Dial Transplant; 2003 Aug; 18(8):1623-30. PubMed ID: 12897104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin is unable to prevent contact activation by three different membranes.
    Stratta P; Canavese C; Mangiarotti G; Pacitti A; Tetta C; Coppo R; Ragni R; Vercellone A
    Proc Eur Dial Transplant Assoc; 1981; 18():269-74. PubMed ID: 6460241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-related hemostasis before and after hemodialysis with five different anticoagulation methods.
    Knehtl M; Ponikvar R; Buturovic-Ponikvar J
    Int J Artif Organs; 2013 Oct; 36(10):717-24. PubMed ID: 24254839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant therapy in a congenital antithrombin III (ATIII)-deficient patient with chronic renal failure undergoing regular hemodialysis.
    Matsuo T; Yamada T; Matsuo M; Sakai R
    Biomater Artif Cells Immobilization Biotechnol; 1991; 19(1):185-91. PubMed ID: 1751668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated beta-thromboglobulin in patients with chronic renal failure: effect of hemodialysis.
    Green D; Santhanam S; Krumlovsky FA; del Greco F
    J Lab Clin Med; 1980 May; 95(5):679-85. PubMed ID: 6154114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent heparin-induced thrombocytopenia due to heparin rinsing before priming the machine in a hemodialysis patient: A case report.
    Lim JH; Kang KP; Lee S; Park SK; Kim W
    Hemodial Int; 2017 Apr; 21(2):E30-E33. PubMed ID: 27734602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of an anticoagulant (heparin versus nafamostat mesilate) on the extrinsic coagulation pathway in chronic hemodialysis.
    Matsuo T; Matsuo M; Kario K; Koide M
    Blood Coagul Fibrinolysis; 1998 Jun; 9(4):391-3. PubMed ID: 9690813
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of ex vivo anticoagulants on whole blood platelet aggregation.
    Kalb ML; Potura L; Scharbert G; Kozek-Langenecker SA
    Platelets; 2009 Feb; 20(1):7-11. PubMed ID: 19172515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.